Synlogic Provides Corporate Update and Outlook for 2024
Provided By GlobeNewswire
Last update: Jan 4, 2024
- Data review from pivotal Synpheny-3 study in PKU expected in H1 2024, with potential to expand study population to patients aged 12-17 years of age -
- Top-line, Phase 3 data in PKU expected in H1 2025 -
Read more at globenewswire.comNASDAQ:SYBX (8/22/2025, 8:00:00 PM)
1.46
+0.06 (+4.29%)
Find more stocks in the Stock Screener
